RocketTickers

Enzyvant Receives FDA Approval for RETHYMIC® (allogeneic process

NYSE:MYOV   None
MYOV: Enzyvant
2021-10-09 20:09:51
Enzyvant Receives FDA Approval for RETHYMIC® (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athymia

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.